Incara cell line could speed artificial liver:
This article was originally published in Clinica
Incara Pharmaceuticals is to be awarded a patent on an isolated hepatocyte precursor cell, which can differentiate into a hepatocyte. It plans to inject these cells, which have the potential to grow into functioning liver tissue, into patients as an alternative to whole organ transplant or for patients ruled out for that procedure. Such a cell line would also have potential for those companies presently researching the development of a bioartificial liver device.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.